References
- Boyd EL. Mail order prescriptions: the controversy continues. Mich Pharm 1986 Jan 24: 24: 4–9
- Raven M. Chains form up to meet nontraditional opponents. Drug Top 1985 Apr 15: 129: 44–6
- Chi J. New rivals spell tough sledding for drugstores. Drug Top 1984 Dec 10: 128: 44–6
- Bloom BS, Wierz DJ, Pauly MV. Cost and price of comparable branded and generic pharmaceuticals. JAMA 1986: 256(18): 2523–30
- Warren AS. Ephlin DF. Communication from General Motors and UAW regarding mail order prescription drug program effective April 1, 1984
- Stoffer SS, Szpunar WE. Drug substitution encouraged by law. (Letter) JAMA 1981: 246(14): 1545
- Proceedings of Food and Drug Administration Bioequivalence Hearing. Washington. DC: 1986 Sep: 713
- Staffer SS, Szpunar WE. Potency of brand name and generic levothyroxine products. JAMA 1980: 244(15): 1704–5
- Stoffer SS, Szpunar WE. Potency of levothyroxine products. JAMA 1984: 251 (5): 635–6
- Fish LH, Schwartz HL, Cavanaugh J, et al. Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hyperthyroidism: role of trliodothyronine in pituitary feedback in humans. N Engl J Med 1987: 316(13): 764–70
- Dong BJ, Young VR, Rapoport B. The nonequivalence of levothyroxine products. (Letter) Drug Intell Clin Pharm 1986: 20(1): 77–8